Respiratory Syncytial Virus–Associated Hospitalizations Among Adults With Chronic Medical Conditions

Overview of attention for article published in Clinical Infectious Diseases, June 2020

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (83rd percentile)

Mentioned by

news: 9 news outlets
policy: 1 policy source

twitter: 2 X users
guideline: 2 clinical guideline sources

Readers on

mendeley: 79 Mendeley

So far, Altmetric has seen 12 news stories from 9 outlets.

Santé Canada accepte d'examiner Arexvy, le vaccin de GSK contre le VRS, pour prévenir le virus chez les adultes de 50 à 59 ans présentant un risque accru d'infection

Le Lézard, 26 Feb 2024

MISSISSAUGA, ON Cette présentation fait suite à l'approbation, en août 2023, d'Arexvy au Canada Les personnes qui ont des…

GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk

benzinga, 26 Feb 2024

Submission supported by positive results of a Phase III study showing immune response and tolerability in adults aged 50-59…

GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk

Yahoo! Finance USA, 26 Feb 2024

Submission supported by positive results of a Phase III study showing immune response and tolerability in adults aged 50-59…

GSK's RSV vaccine, Arexvy, accepted for review by Health Canada for prevention of RSV disease in adults aged 50-59 at increased risk

Le Lézard, 26 Feb 2024

MISSISSAUGA, ON This submission follows the August 2023 People with underlying medical conditions, such as chronic obstructive…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 8 additional news stories.